Indications and Orphan Designations

Impavido is the first and only FDA-approved drug to treat cutaneous or mucosal leishmaniasis, in addition to Viceral leishmaniasis.


Impavido (Miltefosine) is promising with an orphan designation for the treatment of free-living ameba (FLA) infections caused by Naegleria fowleri, Balamuthia mandrillaris, Amebiasis, Schistosomiasis, Granulomatous Amebic
Encephalitis (GAE) and Acanthamoeba species. Use of Impavido with these Orphan Designations is considered "off-label" use at this time.


Please contact us to learn more 

 Impavido® (miltefosine) is an FDA-approved treatment for cutaneous,  mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO 


Contact Your Doctor or the CDC to Learn More about IMPAVIDO (miltefosine)

Impavido is a registered trademark of Knight Therapeutics Licensed exclusively to Profounda in the USA

© 2015 Profounda, Inc. 

For Emergencies
Call 911